[Prevalence of HBV and HCV markers in patients of specialized medical institutions].

240 medical histories of patients admitted to Moscow clinical narcological hospital No. 17 with "opium addiction" diagnosis in 2000 and 2003 (120 histories for each year) were analyzed. From 1997 to 2003 4220 patients registered in narcological dispensary of Cherepovets city (Vologda region) were tested for HBsAg and anti-HCV. It has been shown that in new injection opiate drug users young patients (15 - 19 y.o.) predominated (41.7%). Tendency to development of drug addiction in younger age was revealed - in 2003 compared to 2001 percent of new injection drug users aged 11 - 14 years admitted to hospital raised in 1.5 times. In 2000 and 2003 in Moscow markers of HIV and/or HBV/HCV infection were detected in 84.2 and 91.7% of injection drug users respectively. Maximal rates of HBV and HCV infection in injection drug users in Cherepovets city were detected in 2001 - 11.7 and 83.1% respectively. Leading role of injection drug users in maintenance of HBVand HCV epidemic process activity in Russia was established.

[A comparative evaluation of detection of antibodies to hepatitis C virus in different immunoassay test system and verification tests]. / Sravnitel'naia otsenka rezul'tatov opredeleniia antitel k virusu gepatita C pri ispol'zovanii razlichnykh immunofermentnykh test-sistem i podtverzhdaiushchikh testov.

Control tests and subsequent comparative analysis of their results related with the detection of anti-hepatitis C virus (anti-HCV) by different ELISA systems were made at a laboratory of the "Vector-Best" Company, Novosibirsk (A), a clinical diagnostic laboratory of Infection Clinical Hospital No. 1, No. 1 (B), and at a laboratory of chronic viral infections of Andjaparidze Institute of Viral Drugs of the Russian Academy of Medical Sciences (C). Two thousand three hundred and fifty blood sera of donors and 236 blood sera of patients with acute and chronic renal pathology were examined. The comparative research made at the above facilities by different ELISA systems produced diversified results. An analysis of 2350 blood samples from donors made in 3 ELISA systems at laboratory A showed divergence in 19 (0.8%) cases. At laboratories B and C, 5 ELISA systems (a set of 236 samples) denoted differences in 28 (11.9%) cases. Significant variances were registered in confirmation of disputable results of ELISA with immunoblot, which is apparently related with differing criteria applicable to confirming the positive results from using the confirmative tests. A possibility is discussed of using different ELISA systems in screening examination.